Show simple item record

dc.contributor.authorHowell, Sacha J
dc.date.accessioned2013-03-15T16:49:57Z
dc.date.available2013-03-15T16:49:57Z
dc.date.issued2013-02
dc.identifier.citationAdvances in the treatment of luminal breast cancer. 2013, 25 (1):49-54 Curr Opin Obstet Gynecolen_GB
dc.identifier.issn1473-656X
dc.identifier.pmid23299092
dc.identifier.doi10.1097/GCO.0b013e32835c0410
dc.identifier.urihttp://hdl.handle.net/10541/273005
dc.description.abstractRecent advances in the genomic analysis of breast cancers show promise in better defining endocrine sensitive subtypes. In addition, several key trials have recently reported results that better define the optimal sequence of endocrine agents and approaches to overcome endocrine resistance.
dc.language.isoenen
dc.rightsArchived with thanks to Current opinion in obstetrics & gynecologyen_GB
dc.titleAdvances in the treatment of luminal breast cancer.en
dc.typeArticleen
dc.contributor.departmentThe University of Manchester, Institute of Cancer Studies, Manchester, UK.en_GB
dc.identifier.journalCurrent Opinion in Obstetrics & Gynecologyen_GB
html.description.abstractRecent advances in the genomic analysis of breast cancers show promise in better defining endocrine sensitive subtypes. In addition, several key trials have recently reported results that better define the optimal sequence of endocrine agents and approaches to overcome endocrine resistance.


This item appears in the following Collection(s)

Show simple item record